Navigation Links
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Date:8/19/2007

SAN DIEGO, Aug. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ANX-510, or CoFactor(R) injection, which is currently being investigated in a pivotal Phase 3 study, with 5-fluorouracil (5-FU) and bevacizumab for the initial treatment of metastatic colorectal cancer. CoFactor is a folate-based biomodulator drug designed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU.

"The FDA's fast track designation represents a significant step towards bringing CoFactor to market as rapidly as possible," stated Evan M. Levine, chief executive officer of ADVENTRX. "We look forward to working closely with the FDA to expedite the review and approval process for CoFactor."

The fast track programs of the Food and Drug Administration (FDA) are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast track status enables a sponsor to have more frequent and timely communication and meetings with the FDA regarding product development plans and may also result in eligibility for priority review of New Drug Applications. Fast track designation does not apply to a product alone but a combination of a product and specific indication.

ADVENTRX is currently conducting a 1,200-patient, Phase 3 clinical study of CoFactor for the tre
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. Adventrx Announces Positive Data From Multidrug Therapy With CoFactor
3. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... Registreer nu via  http://bit.ly/ag8Sypm14de ... Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen (PMR) ... PROGRAMM ™ 2015 in Amsterdam ... Tagung soll dazu beitragen, der Aegate PMR ... profitablen Unternehmensdienstleistungen, die für Apotheken und die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the ... a company overview at J.P. Morgan,s 29th Annual Healthcare Conference ... the Westin St. Francis Hotel in San Francisco, CA. ... be available on the "Investors & Media" section of the ...
... Mass., Jan. 6, 2011 Saints Medical Center, a ... is pleased to announce it has entered into a ... ZOLL ) of Chelmsford, Mass., a leader in comprehensive ... Saints-based EMS service working with ZOLL to collaborate on ...
Cached Medicine Technology:Isis Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement 2Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement 3
(Date:12/21/2014)... December 21, 2014 When families in Coral ... do they call? The new answer is Lice Troopers ... FL 33134, their newest treatment center will be the new ... conveniently and without the use of harmful chemicals or pesticides. ... for January 1, 2015. Like the company’s first clinic (located ...
(Date:12/21/2014)... Thompson HealthDay Reporter FRIDAY, ... e-cigarettes less addictive than traditional cigarettes, new research finds. ... did regular cigarettes, thousands of ex-smokers said they have fewer ... over their need to smoke, researchers reported. ... less for e-cig use than for tobacco use," said lead ...
(Date:12/21/2014)... December 21, 2014 AlignLife of Norton ... need while at the same time helping people get their ... non-profit community-based organization committed to serving those persons in Muskegon ... needs to improve the quality of life. Dr. Michael Rykse ... impact in the local community and he knew he found ...
(Date:12/21/2014)... Over the past 39 years, NES ... of emergency departments across the nation, from quality of ... translated into an innovative suite of tools, systems, and ... enhance the patient experience. , NES Health, a ... management services for hospitals, announced the development and launch ...
(Date:12/21/2014)... December 21, 2014 As testosterone ... heart attacks, stroke and blood clots from using testosterone ... a new study shows that the male hormone testosterone ... In a study published in the Proceedings of the ... Amos-Landgraf examined a group of male rats with naturally ...
Breaking Medicine News(10 mins):Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4
... believe they have found a gene that predisposes people to ... 262 families with alcoholic members all were assessed for three ... been linked to alcoholism. ,Results showed one of ... risk. Researchers aren’t sure how the gene predisposes someone to ...
... required for success in school are similar to those ... that one’s cognitive abilities predict success in the academic ... believe what is needed for job success is different ... the University of Illinois tested whether abilities related to ...
... has been the only treatment for a deteriorated hip joint. ... the traditional replacements.// ,Bobby Castor plays on his school’s ... to a condition called avascular necrosis. Decreased blood flow caused ... golf swing, it hurt Castor’s game. “I was just limping ...
... have steadily increased their consumption of chicken from 32 ... 81 pounds per person in 2000. ,A new study ... than other poultry or meat. Arsenic is an approved ... parasites in chickens. ,Researchers from the National Institutes ...
... drug that strongly activates certain systems in the brain.// ... is often addictive. According to the 2000 National Household ... the United States have tried methamphetamine at least once ... methamphetamine users and 18 healthy people to determine how ...
... that infects and destroys T-cells in the immune system. ... there are between 800,000 and 900,000 people living with ... less likely to be infected with HIV, and a ... from nine specimens of human foreskin. They found each ...
Cached Medicine News:
Ultra-fine 5 mm tying platform is valuable when manipulating delicate 10-0 and 11-0 sutures. Pin in handle keeps tips in alignment. Shafts available straight or angled 45 degrees, 8 mm from tip. Stra...
Angled 45 degree shafts with tying platform. Wide serrated handle with dull finish. Overall length 4.2 inches....
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Curved shafts. Overall length 3.9 inches....
Slightly curved 10 mm jaws and serrated cross action handle with polished finish. Overall length 4.6 inches....
Medicine Products: